Who are RITONAVIR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Darunavir/Cobicistat (FDC), Atazanavir/Ritonavir + Famotidine, elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil, elvitegravir/cobicistat/emtricitabine/tenofovir, Darunavir, Ritonavir, Truvada, Symtuza® (TAF/FTC/DRV/c).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl163.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

RITONAVIR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RITONAVIR (RITONAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytochrome P450 3A Inhibitor [EPC].

marketed Cytochrome P450 3A Inhibitor [EPC] CYP3A Small molecule Live · refreshed every 30 min

Target snapshot

RITONAVIR (RITONAVIR). Lopinavir and ritonavir tablets increase lopinavir plasma levels by inhibiting its CYP3A-mediated metabolism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RITONAVIR TARGET	RITONAVIR		marketed	Cytochrome P450 3A Inhibitor [EPC]	CYP3A	1996-01-01
Darunavir/Cobicistat (FDC)	Darunavir/Cobicistat (FDC)	Janssen Scientific Affairs, LLC	marketed	HIV protease inhibitor with pharmacokinetic booster	HIV protease; CYP3A4
Atazanavir/Ritonavir + Famotidine	Atazanavir/Ritonavir + Famotidine	Bristol-Myers Squibb	marketed	HIV protease inhibitor (boosted) + H2-receptor antagonist	HIV protease; CYP3A4 (ritonavir); H2 receptor (famotidine)
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	Fundacion Clinic per a la Recerca Biomédica	marketed	Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, CYP3A4, HIV reverse transcriptase
elvitegravir/cobicistat/emtricitabine/tenofovir	elvitegravir/cobicistat/emtricitabine/tenofovir	Juan A. Arnaiz	marketed	Antiretroviral combination (INSTI + pharmacokinetic booster + NRTIs)	HIV integrase, CYP3A4, HIV reverse transcriptase
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytochrome P450 3A Inhibitor [EPC] class)

· 2 drugs in this class
Gilead Sciences · 2 drugs in this class
AbbVie · 1 drug in this class
Abbvie Deutschland Gmbh Co. Kg · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RITONAVIR — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl163. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing